Article
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.
Blood - 21 Jun 2018
Patel Sanjay S, Kuo Frank C, Gibson Christopher J, Steensma David P, Soiffer Robert J, Alyea Edwin P, Chen Yi-Bin A, Fathi Amir T, Graubert Timothy A, Brunner Andrew M, Wadleigh Martha, Stone Richard M, DeAngelo Daniel J, Nardi Valentina, Hasserjian Robert P, Weinberg Olga K
Abstract excerpt
Acute myeloid leukemia (AML) with mutated NPM1 is a newly recognized separate entity in the revised 2016 World Health Organization classification and is associated with a favorable prognosis. Although previous studies have evaluated NPM1 in a binary fashion, little is known about the significance of its mutant allele burden at diagnosis, nor has the effect of comutations (other than FLT3) been extensively...
Topics
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- DNA (Cytosine-5-)-Methyltransferases
- DNA Methyltransferase 3A
- Disease-Free Survival
- Female
- Gene Frequency
- Humans